Requests that the FDA Abolish Prescription Gatekeeping for Biological Baselines; Authorize Low-Potency Access and Establish a Neurodivergent Bodily Sovereignty Waiver.
🏛 Food and Drug Administration (FDA)FDA-2026-P-6296
Documents
2
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Jun 3, 2026No comment period